Meet the 7% Yield Dividend Stock That Could Soar in 2026

Key Points The big near-term headwind for this drug maker is upcoming patent expirations. The company is working to address the issue, with a sizable acquisition that will advance its efforts in the diet drug space. Management has also been working with the U.S. government to better position itself for changing regulations. 10 stocks we like better than Pfizer › Pfizer (NYSE: PFE) is one of the oldest and most respected pharmaceutical companies in the world. The stock is out of favor right now, tr ...